Research programme: haemophilia and lysosomal therapeutics - REGiMMUNE

Drug Profile

Research programme: haemophilia and lysosomal therapeutics - REGiMMUNE

Alternative Names: RGI 5000

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REGiMMUNE
  • Class Enzymes; Small molecules
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Haemophilia; Lysosomal-storage diseases

Highest Development Phases

  • Preclinical Haemophilia; Lysosomal-storage diseases

Most Recent Events

  • 22 Sep 2015 Preclinical trials in Haemophilia in Japan (unspecified route) before September 2015
  • 22 Sep 2015 Preclinical trials in Lysosomal storage diseases in Japan (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top